Q32 Bio Inc. (LON:0T6G)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 197.18M +1,062.8% |
| Revenue (ttm) | 40.50M |
| Net Income | 25.46M |
| EPS | 1.71 |
| Shares Out | n/a |
| PE Ratio | 7.74 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,138 |
| Open | 9.67 |
| Previous Close | 9.12 |
| Day's Range | 8.97 - 9.67 |
| 52-Week Range | 1.82 - 23.50 |
| Beta | -0.38 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 6, 2026 |
About Q32 Bio
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatm... [Read more]
News
Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026
-- Late-breaking oral and poster presentations to feature additional 36-week results and initial findings from the 16-week off-drug period from Part B of the SIGNAL-AA clinical trial of bempikibart in...
Q32 Bio Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The session highlighted strong phase II results for bempikibart in alopecia areata, with robust efficacy, durable responses, and a favorable safety profile. The addressable U.S. market is estimated at $5 billion, with biologics expected to become the preferred treatment. Phase III is fully funded and will leverage phase II learnings.
Q32 Bio Appoints José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D.
-- Dr. Trevejo is a physician-scientist and biotechnology executive with over 20 years of experience spanning dermatology and late-stage clinical development -- -- Dr. Hershberger is a drug developmen...
Q32 Bio Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Bempikibart demonstrated strong efficacy and safety in alopecia areata, with a multibillion-dollar U.S. market opportunity and low current biologic penetration. Phase III is planned as a single pivotal study, with key data and regulatory milestones expected over the next year.
Q32 Bio Transcript: Wells Fargo 21st Annual Healthcare Conference
Positive phase II data for bempikibart in alopecia areata show JAK-like efficacy and a strong safety profile, with plans to advance to phase III and explore additional indications. Upcoming milestones include new data releases, regulatory guidance, and pipeline expansion decisions.
Q32 Bio to Participate in Upcoming September Investor Conferences
WALTHAM, Mass., Sept. 1, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and ...
Q32 Bio initiated with an Overweight at Morgan Stanley
Morgan Stanley initiated coverage of Q32 Bio (QTTB) with an Overweight rating and $34 price target Q32 is a clinical-stage immunology company developing bempikibart for severe or very severe alopecia…
Q32 Bio Quarterly report: Q2 2026
Q32 Bio has published its Q2 2026 quarterly earnings report on August 5, 2026.
Q32 Bio Earnings release: Q2 2026
Q32 Bio released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Q32 Bio Slides: Corporate presentation
Q32 Bio has posted slides in relation to its latest quarterly earnings report, which was published on August 5, 2026.
Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
-- Reported positive bempikibart 36-week topline results from Part B of SIGNAL-AA clinical trial; additional details from 36-week results and initial findings from 52-week results to be presented at a...
Q32 Bio price target raised to $36 from $13 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Q32 Bio (QTTB) to $36 from $13 and keeps a Buy rating on the shares. The firm says the positive week 36…
Q32 Bio files to sell 6.88M shares of common stock for holders
16:15 EDT Q32 Bio (QTTB) files to sell 6.88M shares of common stock for holders
Q32 Bio Registration statement: Registration filing
Q32 Bio filed a registration statement on July 17, 2026, providing details about a securities offering with the SEC.
Q32 Bio 6.03M share secondary priced at $18.25
The deal priced below last closing price of $18.46. Morgan Stanley, Jefferies, Cantor Fitzgerald, Oppenheimer and H.C. Wainwright are acting as joint book running managers for the offering. Published ...
Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants
WALTHAM, Mass., July 14, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB), ("Q32 Bio") a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other a...
Q32 Bio announces $200M common stock offering
Q32 Bio (QTTB) announced that it has commenced an underwritten public offering of $200M of shares of its common stock and, in lieu of common stock to certain investors, pre-funded…
Q32 Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
WALTHAM, Mass., July 13, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB), ("Q32 Bio") a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and ...
Q32 Bio price target raised to $36 from $14 at Mizuho
Mizuho analyst Joseph Catanzaro raised the firm’s price target on Q32 Bio (QTTB) to $36 from $14 and keeps an Outperform rating on the shares following the topline release of…
Why Q32 Bio investors should take profits in the stock after 81% rally
Q32 Bio (QTTB) shares doubled on Monday as the clinical-stage biotech firm announced positive 36-week topline data from Part B of its Phase 2a SIGNAL-AA trial. The trial that evaluated its anti-IL-7R ...
Q32 Bio price target raised to $40 from $20 at Oppenheimer
Oppenheimer raised the firm’s price target on Q32 Bio (QTTB) to $40 from $20 and keeps an Outperform rating on the shares. The firm views today’s SIGNAL-AA Part B data…
Q32 Bio upgraded to Overweight at Wells Fargo after alopecia areata study data
As previously reported, Wells Fargo analyst Derek Archila upgraded Q32 Bio (QTTB) to Overweight from Equal Weight with a price target of $66, up from $10, after the company announced…
Q32 Bio upgraded to Overweight from Equal Weight at Wells Fargo
Wells Fargo upgraded Q32 Bio (QTTB) to Overweight from Equal Weight with a $66 price target
Q32 Bio Transcript: Study result
Corrected summary: The SIGNAL-AA Part B phase IIa trial of bempikibart in severe alopecia areata showed a 35.3% mean SALT score reduction and 40% SALT-20 response at 36 weeks, with robust efficacy in both JAK-naive and JAK-experienced patients. Safety was favorable, supporting bempikibart’s potential as a first-line biologic.
Q32 Bio Press release: Study result
Q32 Bio issued a press release on July 13, 2026, disclosing material business information to investors.